Skip to search formSkip to main contentSkip to account menu

rituximab

Known as: AntiCD20, Ig gamma-1 chain C region, Rituximab CD20 Antibody 
A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and… 
National Institutes of Health

Related topics

Related topics

40 relations
10 ML rituximab 10 MG/ML Injection [Rituxan]50 ML rituximab 10 MG/ML InjectionB-Cell LymphomasCytotoxic T-Lymphocytes

Broader (4)

Antineoplastic AgentsAntirheumatic AgentsImmunologic FactorsMonoclonal Antibodies

Narrower (5)

IDEC-C2B8 AntibodyMabtheraRituxanRituximab Biosimilar PF-05280586

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
BACKGROUND Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with… 
Highly Cited
2015
Highly Cited
2015
Rituximab for IgG4-related disease: a prospective, open-label trial
Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in an open-label pilot trial. Methods We… 
Highly Cited
2011
Highly Cited
2011
Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis
Rituximab treatment in high-risk patients with focal segmental glomerulosclerosis directly affects podocyte function and is… 
Highly Cited
2010
Highly Cited
2010
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Review
2009
Review
2009
The many roles of FAS receptor signaling in the immune system.
Review
2009
Review
2009
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated… 
Highly Cited
2008
Highly Cited
2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may… 
Highly Cited
2006
Highly Cited
2006
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin… 
Highly Cited
2005
Highly Cited
2005
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
OBJECTIVE To investigate the safety and efficacy of B cell depletion treatment of patients with active primary Sjögren's syndrome… 
Highly Cited
2003
Highly Cited
2003
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1
Rituximab is an anti-CD20 chimeric mAb effective for the treatment of B-NHL. It can lyse lymphoma cells in vitro through both C… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)